Eli Lilly Hits $1 Trillion Valuation Amid Strong Bullish Momentum

Eli Lilly stock has reached a historic milestone. With its leap to a new all-time high, the pharmaceutical company surpassed the $1 trillion market capitalization mark for the first time. The rally was driven by continued strong growth and high demand for the company’s key products.

This raises the question of whether the biotech stock can continue its upward trajectory or take a breather after its impressive price performance. The following chart analysis illustrates what the future holds for the stock.

​Chart analysis of Eli Lilly stock

Eli Lilly shares rose by over 7% last Friday, reaching a new all-time high of $1,208.12. In after-hours trading, the price even climbed above $1,220. This pushed the world’s most valuable pharmaceutical company past the $1 trillion mark in market capitalization.

Eli Lilly’s share price has reversed course within the support zone and has risen sharply in the last week. The pharmaceutical company’s stock gained almost 13% from its local average last week. The price is now in a price discovery phase, as there are no longer any resistance levels above the current price.

Eli Lilly analysis: The most important indicators at a glance

To assess future price movements, it’s worth taking a look at technical analysis. This involves examining key indicators such as the Relative Strength Index (RSI), the MACD trend indicator, and Elliott Waves on the chart.

RSI and MACD

The RSI on the weekly chart has recently risen. It is currently trading at around 68 points in the neutral zone. The RSI line has crossed above the signal line, creating a bullish crossover. The MACD has also formed a bullish crossover.

The indicators on the weekly chart currently appear optimistic. Both the RSI and the MACD have formed a bullish cross. The indicator situation looks similarly positive on the daily chart, although the RSI has already entered overbought territory.

Elliott Waves

Elliott Wave analysis on the monthly chart shows that the Eli Lilly share price is in a phenomenal uptrend, currently almost 60,000 percent strong. The price is currently completing wave 5, which is part of a larger wave 3.

Eli Lilly’s share price is showing long-term strength. Profit-taking and temporary corrections are not surprising after such massive gains. The overall upward trend remains intact. As long as local support levels hold, the pharmaceutical giant’s share price can continue its positive development.

Eli Lilly and Company (WKN: 858560) is one of the world’s largest pharmaceutical companies. The core business areas of this traditional US company, founded in 1876, are medications for diabetes and obesity.

Eli Lilly is currently experiencing a boom with its weight loss products Mounjaro and Zepbound.
The pharmaceutical company, headquartered in Indianapolis, is listed on the New York Stock Exchange. With a market capitalization of approximately $1.08 trillion, Eli Lilly is the world’s most valuable pharmaceutical company.

__

(Featured image by Nicholas Cappello via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in sharedeals.de. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.